Evidence map›Paper›PMID 40001550›Full record

ReviewBiomolecules2025

The Emerging Role of m6A and Programmed Cell Death in Cardiovascular Diseases.

Haixia Wang, Juanjuan Han, Hui Kong, Ce Ma, Xin-An Zhang

Abstract readReview
In one paragraph

Review in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Cell-Type-Specific WTAP and ALKBH5-Mediated mCNS neuroscience & therapeutics · 2026
    Article
  7. Review
  8. Host mScientific reports · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Haixia WangCollege of Exercise and Health, Shenyang Sport University, Shenyang 110102, China.ORCID 0000-0001-9789-997X
Juanjuan HanCollege of Exercise and Health, Shenyang Sport University, Shenyang 110102, China.
Hui KongCollege of Exercise and Health, Shenyang Sport University, Shenyang 110102, China.
Ce MaSports Training Teaching and Research Office, Shenyang Sport University, Shenyang 110102, China.
Xin-An ZhangCollege of Exercise and Health, Shenyang Sport University, Shenyang 110102, China.ORCID 0000-0002-7854-4134

Funding

Liaoning Province Applied Basic Research Program 2023JH2/101300072Liaoning Province Social Science Planning Fund for 2023 L23ATY003Science and Technology Innovation Program of the General Administration of Sport of China 22KJCX040
6 · The paper itself

Abstract

N6-methyladenosine (m6A) is the most prevalent internal chemical modification in eukaryotic messenger RNA (mRNA), significantly impacting its lifecycle through dynamic and reversible processes involving methyltransferase, demethylase, and binding proteins. These processes regulate mRNA stability, splicing, nuclear export, translation, and degradation. Programmed cell death (PCD), a tightly controlled process encompassing apoptosis, pyroptosis, ferroptosis, autophagy, and necroptosis, plays a crucial role in maintaining cellular homeostasis, tissue development, and function. Recently, m6A modification has emerged as a significant research area due to its role in regulating PCD and its implications in cardiovascular diseases (CVDs). In this review, we delve into the intricate relationship between various PCD types and m6A modification, emphasizing their pivotal roles in the initiation and progression of CVDs such as myocardial ischemia-reperfusion (I/R), atherosclerosis (AS), pulmonary hypertension (PH), cardiomyopathy, doxorubicin (Dox)-induced cardiotoxicity (DIC), heart failure (HF), and myocardial infarction (MI). Our findings underscore the potential of elucidating the roles of m6A and PCD in CVD to pave new pathways for prevention and treatment strategies.

Indexed as

AdenosineApoptosisCardiovascular DiseasesAnimalsAutophagyHumansRNA, MessengerAdenosineN-methyladenosineRNA, Messengeratherosclerosisexercisemyocardial ischemiaN6-methyladenosine (m6A)programmed cell deathpulmonary hypertension

Identifiers

PMID40001550
PMCPMC11853213

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.